RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Innate Pharma Stock

Innate Pharma Dividend 2024

Innate Pharma Dividend

0 EUR

Innate Pharma Dividend yield

Ticker

IPH.PA

ISIN

FR0010331421

WKN

A0LCUJ

How much dividend does Innate Pharma 2024 pay?

According to the latest status from September 2024, Innate Pharma paid a total of 0 EUR per share in dividends within the last 12 months. With the current Innate Pharma price of 1.97 EUR, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Innate Pharma Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Innate Pharma Dividend Safe?

Innate Pharma has been increasing the dividend for 0 years.

Over the past 10 years, Innate Pharma has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Innate Pharma's Dividend Distributions

Innate Pharma’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Innate Pharma's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Innate Pharma's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Innate Pharma’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Innate Pharma Aktienanalyse

What does Innate Pharma do?

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Innate Pharma stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about Innate Pharma stock

How much dividend does Innate Pharma pay?

Over the past 12 months, Innate Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innate Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Innate Pharma?

The current dividend yield of Innate Pharma is .

When does Innate Pharma pay dividends?

Innate Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innate Pharma?

Innate Pharma paid dividends every year for the past 0 years.

What is the dividend of Innate Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innate Pharma located?

Innate Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innate Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innate Pharma from 9/22/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Innate Pharma pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Innate Pharma in the year 2023?

In the year 2023, Innate Pharma distributed 0 EUR as dividends.

In which currency does Innate Pharma pay out the dividend?

The dividends of Innate Pharma are distributed in EUR.

Andere Kennzahlen von Innate Pharma

Our stock analysis for Innate Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.